The Study About the Identification of Treatable Traits of Severe Asthma and the Construction of Personalized Treatment System

Launched by BEIJING CHAO YANG HOSPITAL · Aug 18, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to better understand and treat severe asthma, a condition where asthma symptoms are hard to control even with strong medicines. The researchers want to identify specific “treatable traits” or factors in each patient’s asthma that can be targeted with personalized treatments. By looking at lung tests, allergy information, and other health details, they hope to create a customized care plan that improves asthma control and quality of life. The study will compare this personalized approach to usual asthma care over six months to see which works better.

Adults aged 18 to under 80 years with a confirmed diagnosis of severe asthma—meaning their asthma is not well-controlled despite using strong inhaler medicines—may be eligible. Participants will undergo detailed tests and assessments, and their care will be managed by a team of specialists working together. They will be followed for six months to track how well their asthma is controlled and how their quality of life improves. People with certain other lung diseases, recent surgeries, pregnancy, or specific medication use may not be able to join. This study aims to develop a new, individualized way to manage severe asthma that could help patients feel better and breathe easier.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years, and \<80 years with a definite diagnosis of asthma for at least 6 months
• • Patients met the 2024 GINA criteria for severe asthma, which was defined as "uncontrolled" asthma (frequent asthma symptoms, or frequent acute exacerbations) despite high-dose inhaled corticosteroids (ICS) plus long-acting β2-receptor antagonists (LABAs), or worsening of symptoms after slight tapering of high-dose therapy.
• • They were willing to accept multi-disciplinary and multi-dimensional evaluation and signed informed consent
• • Informed consent was obtained and patients were able to participate in the study and 6-month follow-up according to the protocol
• Exclusion Criteria:
• • The presence of numerous other lung tissue destructive diseases, such as severe bronchiectasis or pulmonary tuberculosis.
• • Chest surgery or abdominal surgery in the past 3 months
• • Eye surgery had been performed within the past 3 months
• • Myocardial infarction within the previous 3 months
• • Anti-tuberculosis treatment is ongoing
• • Women who are pregnant and lactating
• • Macrolide use within 4 weeks before the screening period
• • Treatment with anti-ige, anti-IL-5, or anti-IL-5R within 4 weeks before the screening period
• • Inhaled ICS+LABA+ long-acting anticholinergic agent (LAMA) for 4 weeks prior to the screening period 4. Allergy to macrolides
• • QTc interval prolongation \>480ms
• • Taking medications that interact with azithromycin, causing QTc prolongation or existing ECG abnormalities, may lead to arrhythmia